Document is current
Any future updates will be listed below
-
Authors
Ciscato, Francesco
Filadi, Riccardo
Masgras, Ionica
Pizzi, Marco
Marin, Oriano
Damiano, Nunzio
Pizzo, Paola
Gori, Alessandro
Frezzato, Federica
Chiara, Federica
Trentin, Livio
Bernardi, Paolo https://orcid.org/0000-0001-9187-3736
Rasola, Andrea https://orcid.org/0000-0003-4522-3008
-
Funding
Funding for this research was provided by:
JHU|Neurofibromatosis Therapeutic Acceleration Program
Associazione Italiana per la Ricerca sul Cancro (IG 2017/20749)
Associazione Italiana per la Ricerca sul Cancro (2015/17067)
Children's Tumor Foundation
Università degli Studi di Padova
- License Information
-
More Information
Article History
Received: 21 August 2019
Revised: 22 March 2020
Accepted: 2 April 2020
First Online: 8 May 2020
Conflict of interest
: A patent application was filed by University of Padova for the use of the HK2‐targeting peptide described in the manuscript as an anti‐neoplastic tool in in vitro and in vivo experiments.
